NeuroSense's PrimeC ALS Study Successfully Meets Primary Efficacy Endpoint
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 29 2026
0mins
NeuroSense Therapeutics announced that its Phase 2b PARADIGM study of PrimeC in amyotrophic lateral sclerosis has successfully met its primary efficacy endpoint, demonstrating a statistically significant reduction in TDP-43 levels compared to placebo. This is the first randomized, double-blind, placebo-controlled clinical study to demonstrate a treatment-associated reduction in TDP-43 in people living with ALS. The analysis was performed using the NeuroDex ExoSORT procedure, an immunoaffinity-based methodology that selectively isolates neuron-derived extracellular vesicles. This approach enables measurement of neuron-derived TDP-43, providing a CNS-relevant signal that can be distinguished from TDP-43 released by non-neuronal cells and peripheral tissues. TDP-43 is the defining pathological hallmark of ALS, present in more than 97% of cases, and is widely recognized as a central driver of disease progression. The observed reduction in TDP-43 provides biological evidence that PrimeC is engaging a core disease mechanism.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NRSN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NRSN
Wall Street analysts forecast NRSN stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.696
Low
7.50
Averages
8.25
High
9.00
Current: 0.696
Low
7.50
Averages
8.25
High
9.00
About NRSN
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NeuroSense Participates in ALS Expert Webinar
- Expert Webinar: NeuroSense will participate in a webinar hosted by Roth Capital Partners on July 8, 2026, discussing the current treatment landscape and unmet medical needs in ALS, which is expected to attract leading experts and enhance the company's visibility in the ALS field.
- Clinical Trial Design: The webinar will explore clinical trial endpoint design, particularly how to better capture disease progression, reflecting NeuroSense's leading position in ALS treatment research and potentially guiding future clinical trials.
- PrimeC Drug Prospects: NeuroSense's PrimeC is set to enter the pivotal Phase 3 PARAGON trial, aiming to enroll approximately 300 participants, and if successful, could pave the way for FDA accelerated approval, showcasing its potential market opportunity in ALS treatment.
- Biomarker Data: In the previous Phase 2b PARADIGM study, PrimeC demonstrated significant biological activity and meaningful slowing of disease progression, indicating its multi-target mechanism may provide important survival benefits for ALS patients, further solidifying NeuroSense's market position.
See More
NeuroSense's ALS Study Achieves Breakthrough
- Significant Efficacy: NeuroSense Therapeutics' Phase 2b PARADIGM study demonstrates that PrimeC significantly reduces TDP-43 levels in ALS patients, marking a crucial advancement as the first randomized, double-blind, placebo-controlled trial to show treatment-related efficacy.
- Sustained Effects: Throughout the 18-month study, patients receiving continuous PrimeC treatment maintained lower TDP-43 levels than the placebo group at Day 540, indicating both the durability and deepening of the treatment effect.
- Regulatory Progress: The company has received FDA clearance to initiate its Phase 3 PARAGON study and is actively engaging in regulatory discussions across multiple jurisdictions, including Canada, highlighting the smooth progression of its product development.
- Market Reaction: NeuroSense shares are currently trading at $0.8001, reflecting a 5.64% increase, indicating positive market sentiment towards its research outcomes and recognition of future potential.
See More
NeuroSense Achieves Breakthrough in ALS Study
- Primary Efficacy Endpoint Achieved: NeuroSense's Phase 2b PARADIGM study successfully met its primary efficacy endpoint, demonstrating a statistically significant reduction in TDP-43 levels (p=0.0421) in ALS patients, marking a pivotal moment in ALS research and potentially laying the groundwork for future treatment options.
- Sustained Long-term Effects: Over the 18-month study, PrimeC maintained a significant reduction in TDP-43 levels, with results at Day 540 showing a marked decrease compared to the placebo group (p<0.001), indicating PrimeC's potential effectiveness in ALS treatment.
- FDA Approval for Phase 3 Trial: NeuroSense has received FDA clearance to initiate its global Phase 3 (PARAGON) study, expected to enroll approximately 300 participants, further validating PrimeC's efficacy and safety and advancing its path to market.
- Clinical Significance of Biomarkers: The study results highlight TDP-43 as a pathological marker for ALS, suggesting that PrimeC may engage critical biological pathways such as neuroinflammation and oxidative stress, providing new insights into ALS treatment and enhancing its potential as a disease-modifying therapy.
See More
PrimeC Shows Positive Biomarker Findings in Alzheimer's Disease Study
- Biomarker Findings: The RoAD study in Alzheimer's disease revealed multiple significant biomarker changes for PrimeC, including brain-derived tau and phospho-tau, indicating potential effective targeting of neurodegenerative disease pathways, thereby laying the groundwork for future clinical trials.
- Clinical Trial Design: The RoAD study enrolled eight participants randomized to either PrimeC or placebo, with results showing no serious adverse events during the 12-month follow-up, supporting its safety and tolerability and enhancing confidence in its application in larger trials.
- Multi-Target Mechanism: PrimeC's multi-target mechanism shows promise not only in Alzheimer's but also aligns with findings from its ALS studies, suggesting its potential role across various neurodegenerative diseases, thus increasing its market competitiveness.
- Future Research Directions: NeuroSense intends to leverage these preliminary findings to inform the design of future clinical studies to verify whether PrimeC's biological effects can translate into clinical benefits, further advancing its application in neurodegenerative disease treatment.
See More
NeuroSense Announces New Developments in ALS Research
- Clinical Trial Progress: NeuroSense Therapeutics' PrimeC has demonstrated significant slowing of disease progression in the Phase 2b PARADIGM study for ALS, indicating its potential as a new treatment option that could provide hope for patients.
- FDA Approval for New Trial: The company has received FDA clearance to initiate a pivotal Phase 3 clinical trial (PARAGON) for ALS, expected to enroll approximately 300 participants, paving the way for PrimeC's market prospects.
- Significant Biomarker Findings: Research indicates that PrimeC exhibits substantial biological activity across multiple ALS-related biomarkers, supporting its multi-target mechanism of action, which could transform treatment strategies for ALS.
- Growing Demand for ALS Treatment: The number of ALS patients is projected to increase by 24% by 2040 in the U.S. and EU, highlighting NeuroSense's strategic importance in addressing the rising market demand for effective therapies.
See More
NeuroSense Secures $600,000 in Private Placement Financing
- Financing Size: NeuroSense Therapeutics announced a definitive agreement for a private placement of $600,000, intending to sell 750,000 ordinary shares at $0.80 each, which is 6.7% above the closing price on April 27, indicating strong market confidence in its future prospects.
- Management Participation: CEO Alon Ben-Noon and CFO Or Eisenberg each committed $200,000, reflecting the management's commitment to the financing initiative, while also attracting participation from a significant existing shareholder, thereby bolstering investor confidence.
- Use of Proceeds: The proceeds from this financing will be utilized for general corporate purposes, particularly ahead of upcoming clinical and regulatory milestones, ensuring liquidity at critical junctures to support the company's R&D efforts.
- Compliance Statement: This private placement relies on an exemption under Section 4(a)(2) of the Securities Act, with securities issued not being sold in the U.S., ensuring the company operates within a compliant framework and mitigates legal risks.
See More
NeuroSense Participates in ALS Expert Webinar
- Expert Webinar: NeuroSense will participate in a webinar hosted by Roth Capital Partners on July 8, 2026, discussing the current treatment landscape and unmet medical needs in ALS, which is expected to attract leading experts and enhance the company's visibility in the ALS field.
- Clinical Trial Design: The webinar will explore clinical trial endpoint design, particularly how to better capture disease progression, reflecting NeuroSense's leading position in ALS treatment research and potentially guiding future clinical trials.
- PrimeC Drug Prospects: NeuroSense's PrimeC is set to enter the pivotal Phase 3 PARAGON trial, aiming to enroll approximately 300 participants, and if successful, could pave the way for FDA accelerated approval, showcasing its potential market opportunity in ALS treatment.
- Biomarker Data: In the previous Phase 2b PARADIGM study, PrimeC demonstrated significant biological activity and meaningful slowing of disease progression, indicating its multi-target mechanism may provide important survival benefits for ALS patients, further solidifying NeuroSense's market position.
See More
NeuroSense's ALS Study Achieves Breakthrough
- Significant Efficacy: NeuroSense Therapeutics' Phase 2b PARADIGM study demonstrates that PrimeC significantly reduces TDP-43 levels in ALS patients, marking a crucial advancement as the first randomized, double-blind, placebo-controlled trial to show treatment-related efficacy.
- Sustained Effects: Throughout the 18-month study, patients receiving continuous PrimeC treatment maintained lower TDP-43 levels than the placebo group at Day 540, indicating both the durability and deepening of the treatment effect.
- Regulatory Progress: The company has received FDA clearance to initiate its Phase 3 PARAGON study and is actively engaging in regulatory discussions across multiple jurisdictions, including Canada, highlighting the smooth progression of its product development.
- Market Reaction: NeuroSense shares are currently trading at $0.8001, reflecting a 5.64% increase, indicating positive market sentiment towards its research outcomes and recognition of future potential.
See More
NeuroSense Achieves Breakthrough in ALS Study
- Primary Efficacy Endpoint Achieved: NeuroSense's Phase 2b PARADIGM study successfully met its primary efficacy endpoint, demonstrating a statistically significant reduction in TDP-43 levels (p=0.0421) in ALS patients, marking a pivotal moment in ALS research and potentially laying the groundwork for future treatment options.
- Sustained Long-term Effects: Over the 18-month study, PrimeC maintained a significant reduction in TDP-43 levels, with results at Day 540 showing a marked decrease compared to the placebo group (p<0.001), indicating PrimeC's potential effectiveness in ALS treatment.
- FDA Approval for Phase 3 Trial: NeuroSense has received FDA clearance to initiate its global Phase 3 (PARAGON) study, expected to enroll approximately 300 participants, further validating PrimeC's efficacy and safety and advancing its path to market.
- Clinical Significance of Biomarkers: The study results highlight TDP-43 as a pathological marker for ALS, suggesting that PrimeC may engage critical biological pathways such as neuroinflammation and oxidative stress, providing new insights into ALS treatment and enhancing its potential as a disease-modifying therapy.
See More
PrimeC Shows Positive Biomarker Findings in Alzheimer's Disease Study
- Biomarker Findings: The RoAD study in Alzheimer's disease revealed multiple significant biomarker changes for PrimeC, including brain-derived tau and phospho-tau, indicating potential effective targeting of neurodegenerative disease pathways, thereby laying the groundwork for future clinical trials.
- Clinical Trial Design: The RoAD study enrolled eight participants randomized to either PrimeC or placebo, with results showing no serious adverse events during the 12-month follow-up, supporting its safety and tolerability and enhancing confidence in its application in larger trials.
- Multi-Target Mechanism: PrimeC's multi-target mechanism shows promise not only in Alzheimer's but also aligns with findings from its ALS studies, suggesting its potential role across various neurodegenerative diseases, thus increasing its market competitiveness.
- Future Research Directions: NeuroSense intends to leverage these preliminary findings to inform the design of future clinical studies to verify whether PrimeC's biological effects can translate into clinical benefits, further advancing its application in neurodegenerative disease treatment.
See More
NeuroSense Announces New Developments in ALS Research
- Clinical Trial Progress: NeuroSense Therapeutics' PrimeC has demonstrated significant slowing of disease progression in the Phase 2b PARADIGM study for ALS, indicating its potential as a new treatment option that could provide hope for patients.
- FDA Approval for New Trial: The company has received FDA clearance to initiate a pivotal Phase 3 clinical trial (PARAGON) for ALS, expected to enroll approximately 300 participants, paving the way for PrimeC's market prospects.
- Significant Biomarker Findings: Research indicates that PrimeC exhibits substantial biological activity across multiple ALS-related biomarkers, supporting its multi-target mechanism of action, which could transform treatment strategies for ALS.
- Growing Demand for ALS Treatment: The number of ALS patients is projected to increase by 24% by 2040 in the U.S. and EU, highlighting NeuroSense's strategic importance in addressing the rising market demand for effective therapies.
See More
NeuroSense Secures $600,000 in Private Placement Financing
- Financing Size: NeuroSense Therapeutics announced a definitive agreement for a private placement of $600,000, intending to sell 750,000 ordinary shares at $0.80 each, which is 6.7% above the closing price on April 27, indicating strong market confidence in its future prospects.
- Management Participation: CEO Alon Ben-Noon and CFO Or Eisenberg each committed $200,000, reflecting the management's commitment to the financing initiative, while also attracting participation from a significant existing shareholder, thereby bolstering investor confidence.
- Use of Proceeds: The proceeds from this financing will be utilized for general corporate purposes, particularly ahead of upcoming clinical and regulatory milestones, ensuring liquidity at critical junctures to support the company's R&D efforts.
- Compliance Statement: This private placement relies on an exemption under Section 4(a)(2) of the Securities Act, with securities issued not being sold in the U.S., ensuring the company operates within a compliant framework and mitigates legal risks.
See More
